Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial

Abstract

Rheumatoid Arthritis is associated with an increased risk of cardiovascular disease due to chronic inflammation in additon to other typical risk factors. Changes in the lipid levels usually occur within the first weeks of treatment with tocilizumab and stabilize thereafter.

Analysis of avaible data and the results of ENTRACTE trial failed to show an increased risk of cardiovascular event. Associated with tocilizumab compared to other biologics.

Keywords

• Radiovascular risk
• Lipidogram
• Rheumatoid Arthritis
• Tocilizumab